Cervical cancer diagnostics market seen reaching $12.89 billion by 2030

The Business Research Company says the cervical cancer diagnostics market is expanding on stronger screening, higher awareness and new diagnostic tools. The market is projected to rise from $9.76 billion in 2025 to $10.37 billion in 2026, with North America still the largest regional market.

Why it matters: - The market’s growth reflects more screening and earlier detection efforts for a disease that still drives diagnostic demand worldwide. - Rising cervical cancer cases and wider use of molecular testing are pushing healthcare systems toward more advanced diagnostic tools. - The shift matters because earlier diagnosis can improve treatment outcomes and increase use of lab and pathology services.

What happened: - The Business Research Company published a cervical cancer diagnostics market report dated 2026, with forecasts through 2030 and the broader report title extending to 2035. - The market is projected to grow from $9.76 billion in 2025 to $10.37 billion in 2026, a 6.3% CAGR. - The forecast calls for the market to reach $12.89 billion by 2030, at a 5.6% CAGR. - North America was the largest regional market in 2025. - Asia-Pacific ranked as the second-largest market. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The report links recent growth to expanding cervical cancer screening programs, greater awareness of women’s health, wider access to Pap smear technologies, stronger diagnostic laboratory infrastructure and more cervical cancer cases globally. - Future growth is tied to broader use of molecular diagnostics, more spending on cancer prevention, expanded digital pathology, a stronger focus on early-stage diagnosis and ongoing technology upgrades. - Cancer.net reported in February 2023 that about 13,960 women in the U.S. were diagnosed with invasive cervical cancer. - The company offers a free sample of the report and a full market report. - New analytical features in the 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, plus updated graphics and tables.

Between the lines: - The report points to a market moving from basic screening toward more data-driven diagnostics and digital workflows. - North America’s lead suggests mature screening systems and faster adoption of advanced testing, while Asia-Pacific’s size points to rapid healthcare buildout and rising demand. - The inclusion of new forecasting and scoring tools signals a stronger emphasis on competitive positioning and investment planning, not just market sizing.

What's next: - The market is expected to keep expanding through 2030 as healthcare providers invest in earlier detection and more precise testing. - Wider adoption of molecular diagnostics and digital pathology should shape product demand and lab purchasing decisions. - More prevention programs and screening campaigns are likely to support steady volume growth in diagnostic testing.

The bottom line: - Cervical cancer diagnostics is growing on sustained screening demand, higher disease prevalence and faster adoption of advanced testing methods.